Date of report (Date of earliest event reported): December 1, 2020

Akouos, Inc.

(Exact name of registrant as specified in its charter)



81- 1716654

(State or Other Jurisdiction
of Incorporation)  

File Number)

(IRS Employer
Identification No.)

645 Summer Street
Suite 200
Boston, MA


(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (857) 410-1818

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class


Trading symbol(s)


Name of each exchange on which

Common stock, $0.0001 par value per share




Nasdaq Global Select

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Akouos, Inc. (the “Company”) prepared the corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K (the “Corporate Presentation”). Information from this Corporate Presentation may be used by management of the Company in future meetings regarding the Company. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01.      Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.





Corporate Presentation of Akouos, Inc., dated December 1, 2020


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Date: December 1, 2020


/s/ Karoline K. Shair



Name: Karoline K. Shair, Ph.D., J.D.



Title: Chief Legal Officer & Corporate Secretary

Exhibit 99.1


December 2020


This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectation about timing and execution of anticipated milestones, including our planned IND submissions and initiation of clinical trials; our expectations about our collaborators’ and partners’ ability to execute key initiatives; our expectations regarding our regulatory strategy; and the ability of our product candidates to potentially restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: the initiation, timing, progress, and results of our current and future nonclinical studies and clinical trials and our research and development programs, including our expectation that we will submit an IND application for AK-OTOF, our lead product candidate, for otoferlin-mediated hearing loss to FDA in 2021; our estimates regarding expenses, future revenue, capital requirements, need for additional financing, and the period over which we believe that our existing cash, cash equivalents, and investments will be sufficient to fund our operating expenses and capital expenditure requirements; our plans to develop and, if approved, subsequently commercialize our product candidates; the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for, our product candidates; our expectations regarding our regulatory strategy; our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents, and marketable securities; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential addressable patient population for our product candidates; our commercialization, marketing, and manufacturing capabilities and strategy; our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates; our intellectual property position; our ability to identify additional products, product candidates, or technologies with significant commercial potential that are consistent with our commercial objectives; the impact of government laws and regulations; our competitive position and expectations regarding developments and projections relating to our competitors and any competing therapies that are or become available; developments and expectations regarding developments and projections relating to our competitors and our industry; the impact of the COVID-19 pandemic on our business, results of operations, and financial condition; our ability to maintain and establish collaborations or obtain additional funding; and the other risks and uncertainties that are described in the Risk Factors section of our most recent filings with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements except as required by law. By attending or receiving this presentation, you acknowledge that: you are cautioned not to place undue reliance on these forward-looking statements; you will be solely responsible for your own assessment of the market and our market position; and you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of Akouos, Inc. 1 Forward Looking Statements


2 Genetic Medicine Platform Focused on Inner Ear Disorders Attractive Market with High Unmet Need ~466mm people worldwide with disabling hearing loss, including ~34mm children Multimodal Precision Genetic Medicine Platform Building a platform that enables development of multiple vector-mediated genetic medicine modalities utilizing proprietary AAVAnc vectors and a novel delivery approach to target a broad range of inner ear disorders Potential for Rapid Advancement of Lead Program, AK-OTOF AK-OTOF generated promising nonclinical data and has the potential for rapid clinical readout using auditory brainstem response (ABR) as an objective, clinically accepted efficacy endpoint, potentially leading to platform validation Disciplined Execution to Build Pipeline with Potential for Broad Applicability Demonstrating broad applicability of platform: general alignment with FDA on path to IND submission for AK- antiVEGF; product candidate selected for AK-CLRN1 Value-Add Capabilities and Infrastructure Developing internal cGMP manufacturing with capabilities to supply vector for clinical trials World-Class Management Team with Broad Expertise Purposefully assembled team of experts in auditory anatomy and physiology, otopathology, human genetics, inner ear drug delivery, gene therapy, and rare disease drug development and commercialization


3 Experienced Management Team with Otology, Genetic Medicine, and Rare Disease Drug Development Expertise Emmanuel Simons, Ph.D., M.B.A. Founder, Chief Executive Officer Michael McKenna, M.D. Founder, Chief Medical Officer Morgan Molloy Chief Corporate Development Officer Rabia Gurses Ozden, M.D. Chief Development Officer Gregory Robinson, Ph.D. Chief Scientific Officer Karoline Shair, Ph.D., J.D. Chief Legal Officer John Connelly SVP, Portfolio Strategy, R&D Operations Jennifer Wellman Chief Operating Officer Alan Smith, Ph.D. Chief Technology Officer Sachiyo Minegishi Chief Financial Officer


4 How We Hear Ear Drum Round Window Membrane (“RWM”) Spiral Ganglion Cells Auditory Nerve Oval Window Hensen’s Cells Spiral Ganglion Cells Claudius Cells Inner Hair Cells Outer Hair Cells Pillar Cells Inner Border Cells • Sound enters the ear through the external auditory canal of the outer ear, where it vibrates the ear drum • The sound vibrations are then relayed through the middle ear where they articulate with the cochlea at the oval window • The cochlea contains a long, coiled, ribbon-like epithelial membrane that is suspended between two cochlear fluid compartments • Sensory cells, called hair cells, sense the movement of fluid and convert the fluid waves into nerve impulses that are sent along the auditory nerve to the brain 1 2 3 4


5 Overview of Genetically-Driven Hearing Loss Autosomal Recessive Autosomal Dominant Nonsyndromic Syndromic > 75 genes > 30 genes > 48 > 10 1 of 500 newborns has disabling hearing loss Genetic Causes (80%) Syndromic (15-20%) Nonsyndromic (75-80%) Recessive (80%) Dominant (19%) Mitochondrial & X-Linked (1%) Complex Etiology(20%) • Tens of millions of children with monogenic hearing loss worldwide • Congenital hearing loss recognized as neurodevelopmental emergency by American Academy of Pediatrics • Some of the most common forms of monogenic deafness affect an estimated ~200,000 individuals in the U.S. and Europe • No drugs currently approved for the treatment of sensorineural hearing loss Note: Syndromic hearing loss means, in addition to hearing loss, the individual has other symptoms of medical importance.


6 The Anatomy and Biology of the Inner Ear Are Ideal for One-Time Genetic Medicines While the unique anatomical challenges of delivering to the inner ear have hindered genetic medicine development for hearing disorders, we believe Akouos is uniquely positioned to overcome these delivery challenges Opportunity to Leverage Learnings from Development of Genetic Medicines for the Eye and Brain Unique Advantages of the Inner Ear • Enclosed compartments → opportunity for local, targeted delivery • Reduced immune surveillance → lower impact of neutralizing antibodies • Non-dividing target cells → potential for one-time delivery to provide life-long benefit • Fewer target cells and smaller delivery volume → less vector required for meaningful transgene expression • Anatomy is fully developed at birth → more favorable benefit-risk profile in pediatric populations


7 The Akouos Precision Genetic Medicine Platform Novel Delivery Approach Proprietary AAV Vector Library Multimodal Capabilities Gene transfer targeting loss-of- function mutations Gene knockdown or editing targeting toxic gain-of-function or dominant negative mutations Therapeutic protein expression (e.g., monoclonal antibody) targeting disease pathways responsible for non-monogenic hearing loss


• Designed to allow for the safe and effective delivery of product candidates through the round window membrane • Minimally invasive device delivers product candidates in a fixed volume and at a controlled flow rate • Design allows for distribution of product candidates across the full length of the cochlea 8 Novel, Minimally Invasive Delivery Approach Designed to Enable Efficient Access to Target Cells and Controlled Distribution of Product Candidates Throughout the Cochlea Vent in Stapes / Oval Window Injected Fluid Path Akouos Delivery Device in Round Window


9 AAVAnc80 Exhibits High Transduction Efficiency Compared to Other AAV Capsids Capsid AAV1 AAV2 AAV8 AAVAnc80 Dose 21x 3.5x 7x 1x Multiple independent investigations have shown increased hair cell transduction efficiency of AAVAnc80 relative to other AAV capsids in mouse and non-human primate models 0 20 40 60 80 100 %GFP + O HCs 0 20 40 60 80 100 %GFP + IHCs Apex Base AAVAnc80 Transduces Cochlear Hair Cells More Efficiently than Other AAV Capsids OHCs = outer hair cells; IHCs = inner hair cells; GFP = green fluorescent protein Landegger et al., (2017), Nature Biotechnology 35, 280-284


10 Multi-Dose Tropism Study in Cynomolgus Macaque Showed Efficient Inner Hair Cell Transduction at Three Weeks 75 to 100% of inner hair cells (IHCs) express transgene at 6E10 vg / cochlea in the cynomolgus macaque I n n e r H a i r C e l l T r a n s d u c t i o n ( % ) 100 80 60 40 20 0 0.06 0.5 4 32 2.4E11 vg 6.0E10 vg 1.5E10 vg Dose AAVAnc80-eGFP Cochlear Frequency Position (kHz) Percentage of Inner Hair Cells Expressing GFP Three Weeks Following Administration of an AAVAnc80 Vector Encoding GFP AAVAnc80-GFP Expression in Cynomolgus Macaque Cochlea Across Frequencies and Doses (in Vector Genomes (vg) per Cochlea) OHCs = outer hair cells; IHCs = inner hair cells; SC = supporting cells


11 The High Transduction Efficiency of AAVAnc80 Coupled with Local Delivery to the Inner Ear Compartment Allows for a Dual Vector Approach for Larger Transgenes Ability to deliver transgenes that are larger than 5 kilobases in size creates the potential for broader treatment of genetically-driven hearing loss Percentage of Inner Hair Cells Expressing Transgene Three Weeks Following Administration of Dual AAVAnc80 Vectors Cochlear Frequency Position (kHz) Inner Hair Cell Transduction (%) Functional protein 5’ GFP cDNA 3’ GFP cDNA 5’ GFP cDNA 3’ GFP cDNA GFP mRNA


12 AAVAnc80 Efficiently Transduces Multiple Cell Types in the Inner Ear • Conducted nonclinical studies across three different non-human primate models using GFP as a reporter gene delivered by AAVAnc80 • AAVAnc80 can efficiently transduce multiple target cell populations throughout the cochlea in the primate inner ear • Pre-existing neutralizing antibodies, even at relatively high levels in serum, did not inhibit cochlear cell transduction following intracochlear delivery


13 Multimodal Capabilities Create Potential to Address a Broad Range of Monogenic and Non-Monogenic Inner Ear Disorders Gene Transfer Single Vector Dual Vector Gene Knockdown RNA-interference Therapeutic Protein Expression Gene Editing Nuclease- based Non- nuclease- based CLRN1 OTOF Undisclosed autosomal dominant indications GJB2 Hair Cell Regeneration Vestibular Schwannoma Akouos Precision Genetic Medicine Platform Modality Hair Cells Secreted Proteins Supporting Cells Target Initial pipeline spans multiple vector-mediated modalities and cochlear targets to potentially address inner ear disorders affecting hundreds of thousands of individuals in the U.S. and Europe


Deep Pipeline Highlights Breadth of Platform Product Candidate or Development Program (Indication) Estimated Prevalence (US and EU) Stage of Development Next Planned Milestone Discovery Preclinical Phase 1/2 Pivotal Hair Cells AK-OTOF (OTOF-mediated Hearing Loss) 20,000 ▪ IND Submission AK-CLRN1 (Usher Syndrome Type 3A) 2,000 ▪ Pre-IND Meeting Autosomal Dominant Hearing Disorder Pending Target Selection ▪ Target Announcement Supporting Cells GJB2 (GJB2-mediated Hearing Loss) 200,000 ▪ Candidate Selection Hair Cell Regeneration Pending Target Selection ▪ Target Announcement Secreted Proteins AK-antiVEGF (Vestibular Schwannoma) 200,000 ▪ IND Submission Gene Transfer Gene Transfer + Knockdown Therapeutic Protein Expression AAV-Enabled Modalities: 14


AK-OTOF Overview • AK-OTOF encodes otoferlin, a protein that enables the sensory cells of the ear to release neurotransmitter vesicles, activating auditory neurons • AK-OTOF • Use AAVAnc80 as a delivery vehicle for the OTOF gene • Administer product candidate directly into the inner ear • Delivery Method • Progress and Status • Promising nonclinical data in representative mouse models • Pre-IND meeting with FDA; executing on agreed IND-enabling nonclinical studies • Designing a Phase 1/2 trial for AK-OTOF and plan to file an IND in Q4 2021 • Indication • Treatment of sensorineural hearing loss due to mutations in the otoferlin, or OTOF, gene • Mutations in the OTOF gene are a major cause of genetic nonsyndromic hearing loss • Encodes otoferlin to enable release of neurotransmitter vesicles to activate auditory neurons in response to sound • Auditory neurons then carry electronically encoded acoustic information to the brain allowing us to hear • Mechanism of Action • Estimated 20,000 cases of OTOF-mediated hearing loss in the US and EU • Prevalence 15


Dual Vector Delivery of AK-OTOF Led to Restoration of ABR Thresholds and Long-Term Hearing Recovery in Mice AK-OTOF utilizes a dual vector approach to restore long-term hearing in knock-out mouse models – one AAVAnc80 vector carries the 5’ fragment of OTOF gene and the other AAVAnc80 vector carries the 3’ fragment of the OTOF gene Weeks Post-Injection Click ABR threshold (db SPL) 1 4 10 15 25 30 90 80 70 60 50 40 30 20 10 0 Otof-/-(n=6) Otof-/-(5’ alone; n=3) Otof-/-(5’ + 3’; n=8) Wild-type (n=8) Restoration of ABR Thresholds in Otof Knock-Out Mice Receiving a Dual AAV Vector Expressing OTOF Intracochlear Delivery of AK-OTOF Resulted in Significant, Long-term Hearing Recovery in Otof Knock-Out Mice Click ABR threshold (db SPL) 100 80 60 40 20 0 Approximate Age at ABR Test (Administration at 1 week old) 1 mo 3 mo 7 mo 10 mo Otof-/- + AAVAnc80-hOTOF (n=3 per group) Wild-Type (n=6 at 1 mo; n=3 at 10 mo) Untreated Otof-/-(n=5) 16 Akil et al., PNAS (2019)


17 A Single Dose of AK-OTOF Restored Cochlear Function in Mature Mice Lacking Otoferlin Time re Click Onset (msec) Time re Click Onset (msec) Time re Click Onset (msec) Wild-Type Vehicle Control Otoferlin KO + Vehicle Control Otoferlin KO + AAVAnc80-hOTOF In a nonclinical study, a single dose of AK-OTOF restored cochlear function in mice lacking otoferlin


Planned AK-OTOF Phase 1/2 Clinical Trial Part A Dose Escalation Assess: Safety, tolerability, and bioactivity Part B Cohort Expansion Assess: Safety and effectiveness Up to 5-year clinical follow-up (1) Based on pre-IND meeting with FDA in September 2019. Key Eligibility • Individuals with OTOF-mediated hearing loss • Amenable to surgical delivery and potential for benefit • May enroll children as young as one year old in the expansion phase (1) Administration • Administered to trial participants through a single unilateral intracochlear injection Efficacy Endpoints • Objective and clinically relevant ABR testing and age-appropriate behavioral assessment Timing • Submit IND in Q4 2021 • Intend to file the delivery device along with the investigational product as a combination product (1) 18


AK-antiVEGF Overview • AK-antiVEGF encodes a secreted inhibitor of vascular endothelial growth factor (VEGF) to treat vestibular schwannoma • AK-antiVEGF • Progress and Status • Nonclinical data in mice confirm anti-VEGF protein expression • Initial NHP study supports preliminary tolerability of chronic protein expression • Pre-IND meeting feedback supports IND submission in 2022 • Indication • Treatment of vestibular schwannoma, a common intracranial tumor • Current interventional standard of care consists of surgical removal and/or radiation, both of which typically result in hearing loss and can be associated with significant morbidity • Systemic anti-VEGF has been shown to reduce tumor volume and improve hearing in some patients with vestibular schwannoma • Local delivery may avoid the systemic side effects of high dose intravenous VEGF inhibitor infusion and could remove or reduce the need for other interventions • Mechanism of Action • Estimated 200,000 cases in the US and EU • Prevalence • Uses AAVAnc80 as a delivery vehicle to achieve local, sustained anti-VEGF protein at tumor site • Administer product candidate directly into the inner ear • Delivery Method 19


20 AK-antiVEGF for the Treatment of Vestibular Schwannoma Human Data Demonstrate Ability of Systemic VEGF Inhibitor to Improve Hearing and Reduce Tumor Volume in Some Patients with Vestibular Schwannoma Nonclinical Data in NHPs Demonstrate Delivery of AK-antiVEGF is Well- Tolerated and Results in Potentially Therapeutic Protein Expression AAV-mediated anti- VEGF protein secretion in perilymph Computational Modeling Supports Feasibility of Diffusion to Tumor Site Shifts in ABR thresholds (relative to baseline ABRs in the same ear prior to intracochlear injection) are shown for 1, 2, 3, and 6 months post-intracochlear injection of an AAVAnc80 vector encoding anti-VEGF. Group means (±SD) at each timepoint reflect bilateral measurements in each NHP on study.


21 AK-CLRN1 Overview • AK-CLRN1 encodes clarin-1, a protein believed to modulate cochlear hair cell mechanotransduction and synaptic function, for patients with Usher syndrome type 3A • AK-CLRN1 • Progress and Status • Published data demonstrate ability of AAV-mediated delivery of mouse CLRN1 to rescue hearing in mouse model of Usher syndrome type 3A • Additional nonclinical data with AAVAnc80-mediated delivery of human CLRN1 demonstrate hearing rescue in mature mice • Product candidate selected • Indication • Treatment of sensorineural hearing loss due to mutations in the CLRN1 gene • Mutations of CLRN1 gene cause syndromic genetic hearing / vision loss, characterized by progressive sensorineural hearing impairment and progressive vision loss • Mutations in CLRN1 gene reduce the production and localization of CLRN-1 protein to hair cell membranes • AK-CLRN1 is intended to treat hearing loss in patients with Usher syndrome type 3A by delivery of a healthy copy of CLRN1 to cochlear hair cells • Mechanism of Action • Estimated 2,000 cases in the US and EU • Prevalence • Uses AAVAnc80 as a delivery vehicle for the CLRN1 gene • Administer product candidate directly into the inner ear • Delivery Method


22 Proof of Concept Data: AAV-mediated Delivery of CLRN1 Recovered Hearing in a Knock-Out Mouse Model •Nonclinical data demonstrated hearing preservation in the KO-TgAC1 mouse model, which recapitulates the auditory phenotype observed in human USH3A patients •AAV delivery of mouse Clrn1 with its endogenous UTR preserves hearing at levels near wildtype animals •Early nonclinical data show that AAVAnc80 encoding human clarin-1 can rescue hearing in mature KO-TgAC1 mice WT KO-TgAC1 KO-TgAC1 + Clrn1 + UTR Restoration of Hearing Thresholds in CLRN1 KO Mice Injected at P2 to P3 ABR Waveforms UTR = untranslated region Geng et al., Scientific Reports (2017)


23 Key Advantages to Our Manufacturing Process Low dose requirements given small size and compartmentalized nature of the inner ear Targeted delivery and high transduction efficiency alleviate the need for large scale production Exclusive access to AAVAnc Vectors for inner ear provides opportunity to optimize production process and secure additional competitive advantage Potential to expand beyond Phase 1/2 Well characterized HEK293 cell suspension and 250 L bioreactor system


Internal Manufacturing Capabilities May Provide Competitive Advantage Expertise in Gene Therapy and Gene Editing • Expertise covers development from vector design through drug product manufacture • Developing scalable manufacturing capabilities, which may allow for significant control over process development timelines and cost • Internal capabilities to process gene therapy batches to support activities through Phase 1/2 clinical trials • Plans to leverage single use, disposable, closed system operations aligned to genetic medicine platform to promote both flexibility and cost-effectiveness • Internal analytical and process development • 250 L single-use bioreactor system using suspension HEK293 cells Building In-House cGMP Manufacturing Capabilities Current Supply from a Well-Established CMO • Agreement with Lonza, which performed manufacturing for pivotal IND-enabling nonclinical studies for the AK-OTOF program and will conduct cGMP manufacturing to support AK-OTOF clinical development 24


25 Recent Accomplishments and Upcoming Milestones Recent Highlights Upcoming Milestones • Upsized IPO: ~$224mm in net proceeds • Expanded leadership team and board of directors • General alignment with FDA on path to IND submission for AK-antiVEGF; target timing for IND submission is 2022 • Product candidate selection of AK-CLRN1 • GJB2 candidate selection (2021) • Target announcements for hair cell regeneration and autosomal dominant hearing disorder programs (2021) • AK-OTOF IND submission (Q4:2021)